Compare NWPX & RIGL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | NWPX | RIGL |
|---|---|---|
| Founded | 1966 | 1996 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Steel/Iron Ore | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 987.9M | 911.8M |
| IPO Year | 1996 | 2000 |
| Metric | NWPX | RIGL |
|---|---|---|
| Price | $97.06 | $50.78 |
| Analyst Decision | Hold | Buy |
| Analyst Count | 2 | 5 |
| Target Price | ★ $111.00 | $63.00 |
| AVG Volume (30 Days) | 108.5K | ★ 187.5K |
| Earning Date | 10-28-2026 | 11-05-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | 4.71 | ★ 1867.68 |
| EPS | ★ 4.55 | 1.32 |
| Revenue | ★ $526,003,000.00 | $294,282,000.00 |
| Revenue This Year | $14.79 | $3.89 |
| Revenue Next Year | N/A | $21.95 |
| P/E Ratio | ★ $36.60 | $38.83 |
| Revenue Growth | 6.79 | ★ 64.15 |
| 52 Week Low | $53.15 | $24.84 |
| 52 Week High | $152.03 | $52.24 |
| Indicator | NWPX | RIGL |
|---|---|---|
| Relative Strength Index (RSI) | 38.94 | 61.97 |
| Support Level | $94.81 | $44.83 |
| Resistance Level | $114.37 | N/A |
| Average True Range (ATR) | 3.54 | 1.53 |
| MACD | 0.26 | 0.30 |
| Stochastic Oscillator | 22.40 | 75.79 |
NWPX Infrastructure Inc is a manufacturer of water-related infrastructure products, and operates in two segments, Water Transmission Systems (WTS), operating as the Northwest Pipe Company brand, and Precast Infrastructure and Engineered Systems (Precast), which includes the brands NWPX Geneva and NWPX Park. WTS manufactures large-diameter, high-pressure steel pipeline systems for use in water infrastructure applications, which are related to drinking water systems. Precast manufactures stormwater and wastewater technology products, high-quality precast and reinforced concrete products, including reinforced concrete pipe (RCP), manholes, box culverts, vaults, and catch basins, pump lift stations, oil water separators, biofiltration units, and other environmental and engineered solutions.
Rigel Pharmaceuticals Inc develops small-molecule drugs for autoimmune, cancer-related, and viral diseases. The firm's primary drug is an oral rheumatoid arthritis drug candidate that has been licensed to AstraZeneca. Astra has taken overall responsibility for developing and marketing the drug and will pay Rigel royalties and milestone payments. Its pipeline product includes TAVALISSE (fostamatinib disodium hexahydrate) tablets, REZLIDHIA (olutasidenib), GAVRETO (pralsetinib), R289, and Ocadusertib (Systemic) - Eli Lilly.